abrdn Life Sciences Investors (NYSE:HQL) Plans $0.56 Quarterly Dividend

abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Monday, May 11th. Stockholders of record on Thursday, May 21st will be given a dividend of 0.56 per share on Saturday, May 30th. This represents a c) annualized dividend and a dividend yield of 12.3%. The ex-dividend date is Thursday, May 21st.

abrdn Life Sciences Investors Stock Down 0.3%

Shares of abrdn Life Sciences Investors stock opened at $18.14 on Tuesday. abrdn Life Sciences Investors has a one year low of $11.92 and a one year high of $18.46. The stock’s fifty day moving average is $16.98 and its 200 day moving average is $16.98.

Institutional Trading of abrdn Life Sciences Investors

A number of hedge funds and other institutional investors have recently bought and sold shares of HQL. Royal Bank of Canada increased its position in abrdn Life Sciences Investors by 53.3% in the first quarter. Royal Bank of Canada now owns 73,475 shares of the company’s stock worth $934,000 after buying an additional 25,542 shares in the last quarter. NewEdge Advisors LLC increased its holdings in abrdn Life Sciences Investors by 43.1% in the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company’s stock worth $412,000 after acquiring an additional 9,785 shares in the last quarter. First Trust Advisors LP increased its holdings in abrdn Life Sciences Investors by 112.2% in the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company’s stock worth $452,000 after acquiring an additional 18,674 shares in the last quarter. Raymond James Financial Inc. increased its holdings in abrdn Life Sciences Investors by 20.3% in the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock worth $4,816,000 after acquiring an additional 63,429 shares in the last quarter. Finally, Clough Capital Partners L P purchased a new stake in abrdn Life Sciences Investors in the 2nd quarter worth approximately $318,000. Hedge funds and other institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.